May 07, 2025

Building and Sharing Dietary Evidence in Cancer Care

Guest Editor’s Note: Several epidemiologic studies have shown an inverse association between healthy dietary patterns and the risk of chronic diseases including cancer. Patients are often interested i...

The ASCO Post

May 07, 2025

Venetoclax-Based Therapy for Patients With Newly Diagnosed Acute Myeloid Leukemia

Two experts discuss strategies and clinical considerations when treating patients with AML who are ineligible for intensive chemotherapy as well as those who are eligible for intensive chemotherapy.

The ASCO Post

May 07, 2025

FDA Approves Anti–PD-1 Antibody for Nasopharyngeal Cancer

The FDA has approved the humanized IgG1 monoclonal anti–PD-1 antibody penpulimab-kcqx with cisplatin or carboplatin and gemcitabine for the first-line treatment of adults with recurrent or metastatic ...

The ASCO Post

May 07, 2025

Pausing vs Continuing BTK Inhibitors at Time of COVID-19 Vaccination in Patients With CLL

Researchers have examined whether patients with chronic lymphocytic leukemia (CLL) should continue to receive Bruton tyrosine kinase (BTK) inhibitors while being vaccinated against COVID-19 infections...

The ASCO Post

May 07, 2025

Influence of ACA on Breast Reconstruction Disparities

Despite steady increases in the rates of immediate postmastectomy breast reconstruction, racial disparities in receipt of the procedure have persisted in the years since the implementation of the Affo...

The ASCO Post

May 07, 2025

Outcomes With HSCT in Pediatric High-Risk AML

A recent study found that hematopoietic stem cell transplantation (HSCT) was associated with improved outcomes in pediatric patients with high-risk acute myeloid leukemia (AML).

The ASCO Post

May 07, 2025

Symptoms Preceding Unplanned Acute Care in Patients With Cancer

In a single-institution cohort study reported in JAMA Network Open, Chang et al identified patterns of symptoms preceding unplanned acute care encounters for patients with cancer.

The ASCO Post

May 07, 2025

Addition of Perioperative Pembrolizumab to Standard of Care in Newly Diagnosed Locally Advanced Head and Neck Cancer

In the phase III KEYNOTE-689 trial, perioperative use of a PD-1 inhibitor given with standard therapy significantly improved event-free survival in newly diagnosed, previously untreated patients with ...

The ASCO Post

May 07, 2025

Is Active Monitoring a Safe Option for Patients With Ductal Carcinoma In Situ?

With right-sizing treatment an aim of many treatment approaches in breast cancer today, ductal carcinoma in situ (DCIS), as well as its overtreatment, has become a potential target of change. Which pa...

The ASCO Post